Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression

Inclusion Criteria:

- Subject is judged by the investigator to be suitable for participation in a 24-week
clinical trial involving open-label lurasidone treatment

- Subject has completed the 6-week treatment period and all required assessments on the
final study visit (Day 42, Visit 8) of either Study D1050235, NCT#00868452 or Study
D1050236, NCT#008668699.

Exclusion Criteria:

- Imminent risk of suicide, injury to self or to others, or damage to property

- Subject has evidence of severe movement disorders.

- Subject tests positive for drugs of abuse (at Visit 8 in Study D1050235, NCT#00868452
or D1050236, NCT#008688699).